Other Meetings

Other Meetings

On-site reporting from other meetings and summits in the hematology/oncology arena

On location

Should Patients With Hairy Cell Leukemia Receive Delayed or Concurrent Rituximab?

For more than 30 years, the standard firstline treatment of hairy cell leukemia (HCL) has been single-agent purine analog therapy, usually cladribine, but a...
On location

CX-01 Combination Associated With High Response Rate in Older Patients With AML

Treatment with CX-01 and standard chemotherapy induced high response rates – including complete responses (CRs) – in older patients newly diagnosed with acute myeloid...
On location

Umbralisib Confers Durable Response, Tumor Reductions in Patients With Relapsed/Refractory Marginal Zone Lymphoma

While rituximab-based treatment has improved outcomes for patients with marginal zone lymphoma (MZL), most patients eventually have a disease relapse. According to results from...
On location

Transgene Levels Not Sufficient for Treatment Decisions in CAR T-Cell–Treated Patients

An analysis of three clinical trials of tisagenlecleucel found that levels of chimeric antigen receptor (CAR) transgene (or the gene that is artificially introduced...
On location

Gilteritinib Superior to Standard Chemotherapy in Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia

Treatment with the oral FLT3/AXL inhibitor gilteritinib led to longer overall survival (OS) in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia (AML), compared with...
On location

Non-Engineered T Cells to Prevent or Treat Relapse in Post-Transplant AML/MDS

Infusion with “non-engineered” adoptive T-cell products induced responses in select patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) who had undergone allogeneic...
On location

Are CAR T-Cell Therapies Moving to Hodgkin Lymphoma?

Results from two studies presented at the 2019 Transplantation & Cellular Therapy Meetings suggest that Hodgkin lymphoma (HL) may be the next target for...
On location

RADIUS: Midostaurin Reduces Post-Transplant Relapse Risk in FLT3-Mutated AML

Post-transplant maintenance therapy with midostaurin was safe and reduced relapse risk in patients with FLT3-mutated acute myeloid leukemia (AML), according to findings from the...
On location

Post-Transplant Ixazomib Maintenance Prolongs Survival in Newly Diagnosed Myeloma

For patients with newly diagnosed multiple myeloma (MM) who relapse following autologous hematopoietic cell transplantation (AHCT), maintenance therapy with the oral proteasome inhibitor (PI)...
On location

Adoptive “Non-Engineered” T-Cell Therapy Shows Preliminary Efficacy in Lymphomas

Chimeric antigen receptor (CAR) T-cell therapies engineered to recognize and destroy CD19 antigens on the surface of lymphoma cells have revolutionized the treatment of...
Advertisement

Current Issue

August 2019, Volume 5, Issue 10

August 2019, Volume 5, Issue 10

This issue features a debate about gun control as a health care issue, a look at blood services in Israel and Palestine, and more.